Nav: Home

New combined treatment shows promise in hepatocellular carcinoma

June 27, 2018

Researchers from the Metabolism and Cancer group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr Sara Kozma, have unveiled a new potential combined treatment for Hepatocellular Carcinoma (HCC), the second cause of cancer mortality worldwide. The combination of mTOR inhibitors together with the mitochondrial inhibitor Phenformin has shown positive results in in vitro HCC cells, leading to a striking increase in tumor-bearing mice overall survival, which has been recently reported in Clinical Cancer Research.

"Currently available therapeutic options for HCC are very limited and offer poor outcomes, prompting the search for new therapeutic approaches", explains Dr. Kozma, last author of the article. "Inhibitors of the mTOR pathway had already been explored as an alternative treatment, given that this pathway is hyperactivated in most HCCs, but they showed little clinical efficacy. However, as recent data suggested that mTOR inhibitors may promote cancer cell survival by maintaining mitochondrial oxidation and/or autophagy, we set out to examine their use combined with inhibitors of mitochondrial activity." she adds.

In their study, researchers show that treatment of HCC cells in vitro with Phenformin, a mitochondrial Complex1 inhibitor, causes a metabolic shift to glycolysis, mitochondrial dysfunction and fragmentation. "These changes sensitize orthotopic liver tumors in mice to dual inhibition of mTOR, which improves tumor-bearing mice overall survival", says Dr. Sonia Veiga, first author of the Clinical Cancer Research paper.

"Given the recent approval of Phenformin in a clinical trial for melanoma, it will be exciting to explore this regimen clinically in HCC", says Dr. Kozma. According to Dr. Veiga, next steps include testing this combination in human samples thanks to collaboration with Bellvitge Unversity Hospital and the Catalan Institute of Oncology, as well as comparing the results obtained with those of current treatments for HCC.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Hepatocellular Carcinoma Articles:

Dogs help in breast carcinoma research
Cancer of the mammary glands in dogs is very similar to human breast carcinoma.
Crizotinib in bronchial carcinoma: New data not informative
After expiry of the limitation period, the manufacturer presented results from a later data cut-off.
Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma
In this issue of JCI Insight, Yasmin Thanavala and colleagues at Roswell Park Cancer Institute evaluated the immune response in a small cohort of patients with advanced hepatocellular carcinoma before and after treatment with sorafenib.
Identifying how Merkel cell polyomavirus infection can cause a lethal carcinoma
A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer.
Vismodegib in basal cell carcinoma: Added benefit not proven
The drug manufacturer presented no suitable data after expiry of the limitation period.
Study shows possible 'key' to improved therapy for adrenocortical carcinoma
A study comprised of 39 international institutions revealed significant new findings about adrenocortical carcinoma, a rare cancer with an often poor prognosis.
New hepatocellular carcinoma prognostic model improves prediction of patient survival
The ITA.LI.CA prognostic system, a model integrating tumor staging, liver function, functional status, and alpha-fetoprotein level, builds on previous models of hepatocellular carcinoma (HCC) prognosis and shows superior survival prediction in Italian and Taiwanese cohorts, according to a study published this week in PLOS Medicine by Alessandro Vitale of Azienda Ospedaliera Universitaria di Padova, Italy, and colleagues.
Merkel cell carcinoma patients who received pembrolizumab often had durable responses
In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC -- a rare, aggressive type of skin cancer -- the clinical response rate was similar to that typically seen with standard chemotherapy, but the duration of the response appeared to be markedly longer.
Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive.
Towards the goal of precision therapy in hepatocellular carcinoma
Hepatocellular carcinoma is a highly lethal disease, therefore effective and tolerable treatment is urgently needed.

Related Hepatocellular Carcinoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".